RecruitingPhase 1NCT07315087

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

12 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

ANCA Associated Vasculitis (AAV)SLE - Systemic Lupus Erythematosus SSc-Systemic Sclerosis IIM- Idiopathic Inflammatory Myopathies Connective Tissue Disease-Associated Thrombocytopenia SLE-ITP

Summary

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called QT-019C for people with anca associated vasculitis (aav), connective tissue disease-associated thrombocytopenia, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.